Physician profile
Kanhya Ton
NPI 1891181277
$2,946.96
in general payments reported to CMS, 2019-2025
33 companies · $379 in 2025
The $379 reported for 2025 was more than what a typical Nurse Practitioner provider received nationally (typical 2025 total: $174).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $400 · 2022: $964 · 2023: $1,204 · 2025: $379.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,583.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,583.08 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $367.74 | 2021-2023 | |
| Dexcom, INC. | $266.40 | 2022-2023 | Dexcom G6 Transmitter |
| Inspire Medical Systems, INC. | $223.40 | 2025 | Inspire |
| Pfizer INC. | $200.26 | 2023 | |
| Amgen INC. | $185.67 | 2021-2023 | Otezla, Repatha, Prolia |
| Lilly USA, LLC | $174.58 | 2021-2025 | Mounjaro, Zepbound |
| Novo Nordisk INC | $165.31 | 2021-2023 | Rybelsus, Ozempic |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.73 | 2021-2023 | Jardiance, Synjardy |
| Biohaven Pharmaceutical Holding Company Ltd. | $118.31 | 2022 | |
| Astrazeneca Pharmaceuticals Lp | $110.52 | 2021-2025 | Breztri, Fasenra, Andexxa |
| Glaxosmithkline, LLC. | $102.56 | 2022-2023 | Trelegy Ellipta, Arexvy, Shingrix |
| Sanofi-Aventis U.S. LLC | $102.35 | 2021-2023 | |
| Atricure, INC. | $90.02 | 2023 | |
| Avanir Pharmaceuticals, INC. | $86.30 | 2022 | |
| Novartis Pharmaceuticals Corporation | $78.19 | 2021-2022 |
Show all 33 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Teva Pharmaceuticals USA, INC. | $53.27 | 2021-2022 | |
| Amarin Pharma, INC. | $48.44 | 2021-2022 | |
| Exact Sciences Corporation | $46.67 | 2023 | Cologuard Collection Kit |
| Biohaven Pharmaceuticals, INC. | $40.98 | 2021 | |
| Jazz Pharmaceuticals INC. | $39.72 | 2025 | |
| Xeris Pharmaceuticals, INC. | $36.07 | 2022-2023 | Gvoke Hypopen |
| Horizon Therapeutics Plc | $35.00 | 2021 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $31.17 | 2023 | Xifaxan |
| Itamar Medical INC | $28.26 | 2025 | Watchpatone |
| E.R. Squibb & Sons, L.L.C. | $27.92 | 2023 | Eliquis |
| Fisher & Paykel Healthcare INC | $25.38 | 2025 | Fisher & Paykel Healthcare |
| Janssen Pharmaceuticals, INC | $25.23 | 2021 | |
| Idorsia Pharmaceuticals US INC | $25.13 | 2022-2023 | Quviviq |
| Kowa Pharmaceuticals America, INC. | $24.00 | 2021-2022 | |
| Sanofi Pasteur INC. | $23.79 | 2023 | |
| Esperion Therapeutics, INC. | $15.28 | 2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $13.71 | 2023 | |
| Hikma Pharmaceuticals USA | $13.60 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kanhya Ton listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.